stockrowViking Therapeutics, Inc.
VKTX Healthcare Biotechnology
- EPS
- −91.6%
- Free cash flow
- −47.0%
Quarter to September 2026, against a year earlier
Follow VKTX
Alert me
Viking Therapeutics, Inc. (VKTX) EPS (diluted)
Viking Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$3.19, compared with −$1.01 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$5.40. Over the past ten years it has ranged from −$3.68 (fiscal 2015) to −$0.36 (fiscal 2019); the current reading is higher than 18% of that period. EPS (diluted) has fallen for 6 consecutive fiscal years. Viking Therapeutics, Inc. ranks 451st of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.19 | — |
| FY2024 | −$1.01 | — |
| FY2023 | −$0.91 | — |
| FY2022 | −$0.90 | — |
| FY2021 | −$0.71 | — |
| FY2020 | −$0.54 | — |
| FY2019 | −$0.36 | — |
| FY2018 | −$0.38 | — |
| FY2017 | −$0.79 | — |
| FY2016 | −$0.90 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$1.55 | — |
| Jun 2026 | −$1.10 | — |
| Mar 2026 | −$1.37 | — |
| Dec 2025 | −$1.38 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $2.11 |
| ELVN Enliven Therapeutics, Inc. compare | −$1.67 |
| DYN Dyne Therapeutics, Inc. compare | −$3.33 |
| CELC Celcuity, Inc. compare | −$4.30 |
| XENE Xenon Pharmaceuticals Inc. compare | −$4.74 |
| VKTX Viking Therapeutics, Inc. | −$5.40 |
| IRON Disc Medicine, Inc. compare | −$6.58 |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$15.19 |
| PBLS Parabilis Medicines, Inc. compare | −$83.02 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item